Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Mallinckrodt
Chinese Patent Office
Cerilliant
Deloitte
Merck
Fish and Richardson
US Department of Justice
Harvard Business School

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,799,331

« Back to Dashboard

Which drugs does patent 7,799,331 protect, and when does it expire?

Patent 7,799,331 protects FLO-PRED and is included in one NDA.

This patent has twelve patent family members in ten countries.
Summary for Patent: 7,799,331
Title:Oral suspension of prednisolone acetate
Abstract: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
Inventor(s): Asotra; Satish (Brampton, CA), Gao; Shen (Botton, CA), Yacobi; Avraham (Englewood, NJ)
Assignee: Taro Pharmaceutical North America, Inc. (Grand Cayman, KY)
Application Number:11/457,197
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Dosage form; Formulation;

Drugs Protected by US Patent 7,799,331

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ALLERGIC REACTIONS ➤ Sign Up
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ASTHMA ➤ Sign Up
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ASTHMA ➤ Sign Up
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ALLERGIC REACTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,799,331

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,206,727 Oral suspension of prednisolone acetate ➤ Sign Up
8,461,139 Oral suspension of prednisolone acetate ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Argus Health
Citi
Moodys
Chinese Patent Office
Fuji
QuintilesIMS
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.